Publication|Articles|November 12, 2025
Supplements and Featured Publications
- Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer
Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer
Listen
0:00 / 0:00
Advertisement
This clinical brief is sponsored by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection of drugs for coverage, reimbursement, or other population-based health care management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
2
What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light
3
Daratumumab Offers Hope for Delaying Progression to Active MM: Peter Voorhees, MD
4
It’s Time to Reimagine Reimbursement for CAR T-Cell Therapy
5









































